OA19845A - Injectable composition. - Google Patents
Injectable composition. Download PDFInfo
- Publication number
- OA19845A OA19845A OA1202000364 OA19845A OA 19845 A OA19845 A OA 19845A OA 1202000364 OA1202000364 OA 1202000364 OA 19845 A OA19845 A OA 19845A
- Authority
- OA
- OAPI
- Prior art keywords
- letrozole
- composition
- days
- pla
- sustained release
- Prior art date
Links
- 239000007972 injectable composition Substances 0.000 title description 2
- 239000000203 mixture Substances 0.000 claims abstract description 205
- HPJKCIUCZWXJDR-UHFFFAOYSA-N Letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 claims abstract description 182
- 229960003881 letrozole Drugs 0.000 claims abstract description 170
- 239000007943 implant Substances 0.000 claims abstract description 64
- 238000007918 intramuscular administration Methods 0.000 claims abstract description 29
- 230000003203 everyday Effects 0.000 claims abstract description 21
- 238000011065 in-situ storage Methods 0.000 claims abstract description 21
- 229920001169 thermoplastic Polymers 0.000 claims abstract description 15
- 239000002245 particle Substances 0.000 claims description 113
- 229920000747 poly(lactic acid) polymer Polymers 0.000 claims description 89
- 230000002459 sustained Effects 0.000 claims description 59
- 238000007873 sieving Methods 0.000 claims description 29
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 27
- 229940079593 drugs Drugs 0.000 claims description 26
- 238000002050 diffraction method Methods 0.000 claims description 25
- 230000036470 plasma concentration Effects 0.000 claims description 25
- 239000003795 chemical substances by application Substances 0.000 claims description 24
- 239000003814 drug Substances 0.000 claims description 23
- 230000036909 Volume distribution Effects 0.000 claims description 21
- 239000002904 solvent Substances 0.000 claims description 17
- 230000036823 Plasma Levels Effects 0.000 claims description 16
- 229940088597 Hormone Drugs 0.000 claims description 13
- 239000005556 hormone Substances 0.000 claims description 13
- 230000001629 suppression Effects 0.000 claims description 13
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 claims description 12
- 206010006187 Breast cancer Diseases 0.000 claims description 12
- 238000002560 therapeutic procedure Methods 0.000 claims description 12
- 229960005309 Estradiol Drugs 0.000 claims description 11
- 239000007787 solid Substances 0.000 claims description 9
- 239000002671 adjuvant Substances 0.000 claims description 8
- 230000000240 adjuvant Effects 0.000 claims description 8
- 238000007922 dissolution test Methods 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- 238000000338 in vitro Methods 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 6
- -1 poly(lactic acid) Polymers 0.000 claims description 6
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- 108010078554 Aromatase Proteins 0.000 claims description 4
- 238000004458 analytical method Methods 0.000 claims description 4
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims description 2
- 229960001603 Tamoxifen Drugs 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 102000014654 Aromatase Human genes 0.000 claims 1
- 239000004626 polylactic acid Substances 0.000 abstract description 14
- 238000006065 biodegradation reaction Methods 0.000 abstract 1
- 230000035492 administration Effects 0.000 description 49
- 238000009472 formulation Methods 0.000 description 18
- 229940087476 Femara Drugs 0.000 description 13
- 229920000642 polymer Polymers 0.000 description 12
- 230000002354 daily Effects 0.000 description 11
- 239000000262 estrogen Substances 0.000 description 8
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 8
- 235000014655 lactic acid Nutrition 0.000 description 8
- 239000004310 lactic acid Substances 0.000 description 8
- YBBLVLTVTVSKRW-UHFFFAOYSA-N Anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 7
- 229960002932 anastrozole Drugs 0.000 description 7
- 239000007927 intramuscular injection Substances 0.000 description 7
- 210000000988 Bone and Bones Anatomy 0.000 description 6
- WVDDGKGOMKODPV-UHFFFAOYSA-N benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 239000002994 raw material Substances 0.000 description 6
- 125000004185 ester group Chemical group 0.000 description 5
- 150000002148 esters Chemical class 0.000 description 5
- 231100000486 side effect Toxicity 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 4
- 235000020127 ayran Nutrition 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 230000002035 prolonged Effects 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 208000006820 Arthralgia Diseases 0.000 description 3
- 101710013859 At1g04680 Proteins 0.000 description 3
- 102100005573 CYP19A1 Human genes 0.000 description 3
- 206010058108 Dyslipidaemia Diseases 0.000 description 3
- 229940028334 Follicle Stimulating Hormone Drugs 0.000 description 3
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 3
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 206010061227 Lipid metabolism disease Diseases 0.000 description 3
- 206010028323 Muscle pain Diseases 0.000 description 3
- 208000000112 Myalgia Diseases 0.000 description 3
- 101700085733 PELA Proteins 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 102000004965 antibodies Human genes 0.000 description 3
- 108090001123 antibodies Proteins 0.000 description 3
- 230000001186 cumulative Effects 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000002609 media Substances 0.000 description 3
- SESFRYSPDFLNCH-UHFFFAOYSA-N Benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 210000000481 Breast Anatomy 0.000 description 2
- 102000003849 Cytochrome P450 Human genes 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N Dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- GCKFUYQCUCGESZ-BPIQYHPVSA-N Etonogestrel Chemical compound O=C1CC[C@@H]2[C@H]3C(=C)C[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 GCKFUYQCUCGESZ-BPIQYHPVSA-N 0.000 description 2
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 2
- 229960002913 Goserelin Drugs 0.000 description 2
- 208000002672 Hepatitis B Diseases 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 229940040129 Luteinizing Hormone Drugs 0.000 description 2
- 102000009151 Luteinizing Hormone Human genes 0.000 description 2
- 108010073521 Luteinizing Hormone Proteins 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- 210000002381 Plasma Anatomy 0.000 description 2
- 229960003604 Testosterone Drugs 0.000 description 2
- 201000005794 allergic hypersensitivity disease Diseases 0.000 description 2
- 239000003886 aromatase inhibitor Substances 0.000 description 2
- 230000001174 ascending Effects 0.000 description 2
- 235000019445 benzyl alcohol Nutrition 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000003247 decreasing Effects 0.000 description 2
- 239000002612 dispersion media Substances 0.000 description 2
- 238000009547 dual-energy X-ray absorptiometry Methods 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 229960002941 etonogestrel Drugs 0.000 description 2
- 238000002657 hormone replacement therapy Methods 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 230000001965 increased Effects 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 210000004914 menses Anatomy 0.000 description 2
- 239000011859 microparticle Substances 0.000 description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N n-methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
- 230000000275 pharmacokinetic Effects 0.000 description 2
- 230000003389 potentiating Effects 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 229940002612 prodrugs Drugs 0.000 description 2
- 230000000284 resting Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 230000001225 therapeutic Effects 0.000 description 2
- 231100000730 tolerability Toxicity 0.000 description 2
- 238000010947 wet-dispersion method Methods 0.000 description 2
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1H-1,2-benzodiazepine Chemical class N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
- PPGAFAOTXHZHCA-UHFFFAOYSA-N 2-methylpropanenitrile Chemical compound C[C](C)C#N PPGAFAOTXHZHCA-UHFFFAOYSA-N 0.000 description 1
- 229940030486 ANDROGENS Drugs 0.000 description 1
- 229940030495 ANTIANDROGEN SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM Drugs 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 229940046844 Aromatase inhibitors Drugs 0.000 description 1
- 229940112871 Bisphosphonate drugs affecting bone structure and mineralization Drugs 0.000 description 1
- 210000004369 Blood Anatomy 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 210000003679 Cervix Uteri Anatomy 0.000 description 1
- 235000010523 Cicer arietinum Nutrition 0.000 description 1
- 240000000464 Cicer arietinum Species 0.000 description 1
- 230000037242 Cmax Effects 0.000 description 1
- GZCGUPFRVQAUEE-KCDKBNATSA-N D-(+)-Galactose Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-KCDKBNATSA-N 0.000 description 1
- 206010013663 Drug dependence Diseases 0.000 description 1
- 206010014698 Endocrine disease Diseases 0.000 description 1
- 210000000232 Gallbladder Anatomy 0.000 description 1
- 208000005594 Glucose-Galactose Malabsorption Diseases 0.000 description 1
- 240000007842 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 108010069236 Goserelin Proteins 0.000 description 1
- 229940030482 HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE Drugs 0.000 description 1
- 230000036499 Half live Effects 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 206010020718 Hyperplasia Diseases 0.000 description 1
- 229940044513 Implanon Drugs 0.000 description 1
- 210000003734 Kidney Anatomy 0.000 description 1
- 206010023648 Lactase deficiency Diseases 0.000 description 1
- 210000004185 Liver Anatomy 0.000 description 1
- 206010025650 Malignant melanoma Diseases 0.000 description 1
- 240000004658 Medicago sativa Species 0.000 description 1
- USSIQXCVUWKGNF-UHFFFAOYSA-N Methadone Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 description 1
- 240000006116 Mirabilis expansa Species 0.000 description 1
- 235000015429 Mirabilis expansa Nutrition 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010049088 Osteopenia Diseases 0.000 description 1
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N Phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 1
- 229940097325 Prolactin Drugs 0.000 description 1
- 102000003946 Prolactin Human genes 0.000 description 1
- 108010057464 Prolactin Proteins 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 235000010575 Pueraria lobata Nutrition 0.000 description 1
- 244000046146 Pueraria lobata Species 0.000 description 1
- 235000002098 Puffbohne Nutrition 0.000 description 1
- GZUITABIAKMVPG-UHFFFAOYSA-N Raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 1
- 229960004622 Raloxifene Drugs 0.000 description 1
- 210000001685 Thyroid Gland Anatomy 0.000 description 1
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 1
- 210000002700 Urine Anatomy 0.000 description 1
- 206010046788 Uterine haemorrhage Diseases 0.000 description 1
- 229940029983 VITAMINS Drugs 0.000 description 1
- 210000003462 Veins Anatomy 0.000 description 1
- 240000006677 Vicia faba Species 0.000 description 1
- 235000010749 Vicia faba Nutrition 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229940046008 Vitamin D Drugs 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- 229940021016 Vitamin IV solution additives Drugs 0.000 description 1
- 229940033942 Zoladex Drugs 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 235000017585 alfalfa Nutrition 0.000 description 1
- 235000017587 alfalfa Nutrition 0.000 description 1
- 201000000736 amenorrhea Diseases 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 230000002280 anti-androgenic Effects 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000038129 antigens Human genes 0.000 description 1
- 108091007172 antigens Proteins 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 235000013527 bean curd Nutrition 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 230000002146 bilateral Effects 0.000 description 1
- BPYKTIZUTYGOLE-IFADSCNNSA-N bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 1
- 150000004663 bisphosphonates Chemical class 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 230000002149 cannabinoid Effects 0.000 description 1
- 229930003827 cannabinoid Natural products 0.000 description 1
- 239000003557 cannabinoid Substances 0.000 description 1
- 210000004027 cells Anatomy 0.000 description 1
- 201000001084 cerebrovascular disease Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000002192 cholecystectomy Methods 0.000 description 1
- 230000001684 chronic Effects 0.000 description 1
- 230000002254 contraceptive Effects 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 201000008739 coronary artery disease Diseases 0.000 description 1
- 230000000875 corresponding Effects 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 238000007580 dry-mixing Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000002996 emotional Effects 0.000 description 1
- 201000001957 endocrine system disease Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing Effects 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 235000015201 grapefruit juice Nutrition 0.000 description 1
- 230000003054 hormonal Effects 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 238000009802 hysterectomy Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000002045 lasting Effects 0.000 description 1
- 230000000670 limiting Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 230000003211 malignant Effects 0.000 description 1
- 229960001797 methadone Drugs 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000013536 miso Nutrition 0.000 description 1
- 238000009806 oophorectomy Methods 0.000 description 1
- 239000003539 oral contraceptive agent Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000036231 pharmacokinetics Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229950010883 phencyclidine Drugs 0.000 description 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- 239000003488 releasing hormone Substances 0.000 description 1
- 238000009256 replacement therapy Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000011120 smear test Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 235000013322 soy milk Nutrition 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 230000001732 thrombotic Effects 0.000 description 1
- 230000000699 topical Effects 0.000 description 1
- 230000002588 toxic Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229930003231 vitamins Natural products 0.000 description 1
- 230000002747 voluntary Effects 0.000 description 1
- 239000003799 water insoluble solvent Substances 0.000 description 1
Abstract
The present invention refers to a letrozole composition suitable for forming an in situ intramuscular implant comprising a sterile biodegradable thermoplastic polymer of polylactic acid (PLA), for administering a patient in need thereof from 0.1-2 milligrams every day.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18382413.5 | 2018-06-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| OA19845A true OA19845A (fr) | 2021-05-26 |
Family
ID=
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3518933B1 (fr) | Méthodes de traitement des fibromes utérins et de l'endométriose | |
| JP6902583B2 (ja) | 頭痛治療用の鼻腔内ｄｈｅ | |
| JP5563227B2 (ja) | ホルモン置換療法のためのドロスピレノン | |
| US20210169778A1 (en) | Injectable composition with aromatase inhibitor | |
| JP2011190275A (ja) | フルベストラント製剤 | |
| KR20150120479A (ko) | 니트라이트의 약제학적 제형 및 이의 용도 | |
| Schultze-Mosgau et al. | Pharmacokinetics and safety of the selective progesterone receptor modulator vilaprisan in healthy postmenopausal women | |
| EP1448168B1 (fr) | Formulation pharmaceutique comprenant du bicalutamide | |
| US20240108603A1 (en) | Material and method for treating cancer | |
| EP3746047B1 (fr) | Composition injectable | |
| OA19845A (fr) | Injectable composition. | |
| JP2008513469A (ja) | アンドロゲン除去によって生じる骨粗鬆症の治療 | |
| JP2000229859A (ja) | 安定なブプレノルフィン経鼻製剤 | |
| NZ767891A (en) | Injectable composition | |
| CN114146086A (zh) | 维替泊芬在制备抗癌性疼痛的药物中的应用 | |
| CN105726464A (zh) | 一种麝香保心丸缓释凝胶剂用于药理研究的供试品制备方法 | |
| JP2007130028A (ja) | 薬剤塗付医療用具 | |
| WO2023244591A1 (fr) | Formulations de phloroglucinol et méthodes d'utilisation | |
| Zou | Controlled release of dexamethasone from fibrin sealant for intratympanic administration in inner ear therapy | |
| RU2548722C1 (ru) | Противоопухолевое лекарственное средство пролонгированного действия на основе противоопухолевого препарата, ингибитора синтеза эстрогенов - анастрозола | |
| WO2023152138A1 (fr) | Microsphères pour libération prolongée de fénofibrate | |
| CN113577051A (zh) | 一种维拉帕米在制备保护软骨细胞缓解骨关节炎的产品中的应用 |